These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
866 related articles for article (PubMed ID: 33578206)
1. COVID-19 and disease-modifying therapies in patients with demyelinating diseases of the central nervous system: A systematic review. Sharifian-Dorche M; Sahraian MA; Fadda G; Osherov M; Sharifian-Dorche A; Karaminia M; Saveriano AW; La Piana R; Antel JP; Giacomini PS Mult Scler Relat Disord; 2021 May; 50():102800. PubMed ID: 33578206 [TBL] [Abstract][Full Text] [Related]
2. Multiple sclerosis, neuromyelitis optica spectrum disorder and COVID-19: A pandemic year in Czechia. Stastna D; Menkyova I; Drahota J; Mazouchova A; Adamkova J; Ampapa R; Grunermelova M; Peterka M; Recmanova E; Rockova P; Rous M; Stetkarova I; Valis M; Vachova M; Woznicova I; Horakova D Mult Scler Relat Disord; 2021 Sep; 54():103104. PubMed ID: 34216998 [TBL] [Abstract][Full Text] [Related]
3. COVID-19 infection after two doses of SARS-CoV-2 mRNA vaccine in multiple sclerosis, AQP4-antibody NMOSD and MOGAD. Yeo T; Quek AML; Yong KP; Tye JSN; Ratnagopal P; Soon DTL; Tan K Mult Scler Relat Disord; 2022 Sep; 65():104003. PubMed ID: 35803084 [TBL] [Abstract][Full Text] [Related]
4. Clinical course and outcome of SARS-CoV-2 infection in multiple sclerosis patients treated with disease-modifying therapies - the Polish experience. Czarnowska A; Brola W; Zajkowska O; Rusek S; Adamczyk-Sowa M; Kubicka-Bączyk K; Kalinowska-Łyszczarz A; Kania K; Słowik A; Wnuk M; Marona M; Podlecka-Piętowska A; Nojszewska M; Zakrzewska-Pniewska B; Jasińska E; Gołuch K; Lech B; Noga M; Perenc A; Popiel M; Lasek-Bal A; Puz P; Maciejowska K; Kucharska-Lipowska M; Lipowski M; Kapica-Topczewska K; Chorąży M; Tarasiuk J; Kochanowicz J; Kulikowska J; Wawrzyniak S; Niezgodzińska-Maciejek A; Pokryszko-Dragan A; Gruszka E; Budrewicz S; Białek M; Kurkowska-Jastrzębska I; Kurowska K; Stępień A; Włodek A; Ptasznik V; Pawełczyk M; Sobolewski P; Lejmel H; Strzalińska K; Maciejowski M; Tutaj A; Zwiernik J; Litwin A; Lewańczyk B; Paprocka I; Zwiernik B; Pawlos A; Borysowicz A; Narożnik A; Michałowska A; Nosek K; Fudala M; Milewska-Jędrzejczak M; Kułakowska A; Bartosik-Psujek H Neurol Neurochir Pol; 2021; 55(2):212-222. PubMed ID: 33856686 [TBL] [Abstract][Full Text] [Related]
5. Risk of COVID-19 infection and severe disease in MS patients on different disease-modifying therapies. Smith TE; Madhavan M; Gratch D; Patel A; Saha V; Sammarco C; Rimler Z; Zuniga G; Gragui D; Charvet L; Cutter G; Krupp L; Kister I; Ryerson LZ Mult Scler Relat Disord; 2022 Apr; 60():103735. PubMed ID: 35398713 [TBL] [Abstract][Full Text] [Related]
7. Management of central nervous system demyelinating diseases during the coronavirus disease 2019 pandemic: a practical approach. ApÓstolos-Pereira SL; Silva GD; Disserol CCD; Feo LB; Matos AMB; Schoeps VA; Gomes ABAGR; Boaventura M; Mendes MF; Callegaro D Arq Neuropsiquiatr; 2020 Jul; 78(7):430-439. PubMed ID: 32609290 [TBL] [Abstract][Full Text] [Related]
8. Evaluating the perspective of patients with MS and related conditions on their DMT in relation to the COVID-19 pandemic in one MS centre in Australia. Seery N; Li V; Nguyen AL; Roos I; Buzzard KA; Atvars R; Taylor N; Tunnell K; Carey J; Dwyer C; Taylor HFL; Baker J; Marriott MP; Kilpatrick TJ; Kalincik T; Monif M Mult Scler Relat Disord; 2020 Nov; 46():102516. PubMed ID: 32957057 [TBL] [Abstract][Full Text] [Related]
9. Tixagevimab and cilgavimab use in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder during anti-CD20 treatment: A single-center experience. Gelibter S; Pirro F; Saraceno L; Susani E; Moioli MC; Puoti M; Agostoni EC; Protti A J Neuroimmunol; 2023 Oct; 383():578199. PubMed ID: 37717427 [TBL] [Abstract][Full Text] [Related]
10. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies. Wingerchuk DM; Carter JL Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135 [TBL] [Abstract][Full Text] [Related]
11. Influence of Disease Modifying Treatment, Severe Acute Respiratory Syndrome Coronavirus 2 Variants and Vaccination on Coronavirus Disease 2019 Risk and Outcome in Multiple Sclerosis and Neuromyelitis Optica. Eisler JJ; Disanto G; Sacco R; Zecca C; Gobbi C J Clin Med; 2023 Aug; 12(17):. PubMed ID: 37685618 [TBL] [Abstract][Full Text] [Related]
12. Immunology of COVID-19 and disease-modifying therapies: The good, the bad and the unknown. Zrzavy T; Wimmer I; Rommer PS; Berger T Eur J Neurol; 2021 Oct; 28(10):3503-3516. PubMed ID: 33090599 [TBL] [Abstract][Full Text] [Related]
13. The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021. Tur C; Dubessy AL; Otero-Romero S; Amato MP; Derfuss T; Di Pauli F; Iacobaeus E; Mycko M; Abboud H; Achiron A; Bellinvia A; Boyko A; Casanova JL; Clifford D; Dobson R; Farez MF; Filippi M; Fitzgerald KC; Fonderico M; Gouider R; Hacohen Y; Hellwig K; Hemmer B; Kappos L; Ladeira F; Lebrun-Frénay C; Louapre C; Magyari M; Mehling M; Oreja-Guevara C; Pandit L; Papeix C; Piehl F; Portaccio E; Ruiz-Camps I; Selmaj K; Simpson-Yap S; Siva A; Sorensen PS; Sormani MP; Trojano M; Vaknin-Dembinsky A; Vukusic S; Weinshenker B; Wiendl H; Winkelmann A; Zuluaga Rodas MI; Tintoré M; Stankoff B Mult Scler; 2022 Aug; 28(9):1424-1456. PubMed ID: 35196927 [TBL] [Abstract][Full Text] [Related]
14. B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran. Safavi F; Nourbakhsh B; Azimi AR Mult Scler Relat Disord; 2020 Aug; 43():102195. PubMed ID: 32460086 [TBL] [Abstract][Full Text] [Related]
15. Disease-modifying therapies, outcomes, risk factors and severity of COVID-19 in multiple sclerosis: A MENACTRIMS registry based study. Zeineddine M; Al-Hajje A; Salameh P; Massouh J; Saab G; Al-Roughani R; Ahmed SF; Al-Mahdawi A; Shalaby N; Inshasi J; Sahraian MA; Gouider R; Mrabet S; Al-Khabouri J; Shayganneja V; Chentouf A; Boumediene F; Yamout B Mult Scler Relat Disord; 2024 Oct; 90():105790. PubMed ID: 39121598 [TBL] [Abstract][Full Text] [Related]
16. Seropositive Neuromyelitis Optica in a Case of Undiagnosed Ankylosing Spondylitis: A Neuro-Rheumatological Conundrum. Ghosh Md R; Roy D; León-Ruiz M; Das S; Dubey S; Benito-León J Qatar Med J; 2022; 2022(3):29. PubMed ID: 35864917 [TBL] [Abstract][Full Text] [Related]
17. Registry of patients with multiple sclerosis and COVID-19 infection in Saudi Arabia. Alshamrani F; Alnajashi H; AlJumah M; Almuaigel M; Almalik Y; Makkawi S; Alsalman S; Almejally M; Qureshi S; Aljarallah S; AlKhawajah N; Kedah H; Alotaibi H; Saeedi J; Alamri A Mult Scler Relat Disord; 2021 Jul; 52():103004. PubMed ID: 34049217 [TBL] [Abstract][Full Text] [Related]
18. Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy. Gadani SP; Reyes-Mantilla M; Jank L; Harris S; Douglas M; Smith MD; Calabresi PA; Mowry EM; Fitzgerald KC; Bhargava P EBioMedicine; 2021 Nov; 73():103636. PubMed ID: 34666226 [TBL] [Abstract][Full Text] [Related]
19. COVID-19 and the risk of CNS demyelinating diseases: A systematic review. Lotan I; Nishiyama S; Manzano GS; Lydston M; Levy M Front Neurol; 2022; 13():970383. PubMed ID: 36203986 [TBL] [Abstract][Full Text] [Related]
20. Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis. Simpson-Yap S; De Brouwer E; Kalincik T; Rijke N; Hillert JA; Walton C; Edan G; Moreau Y; Spelman T; Geys L; Parciak T; Gautrais C; Lazovski N; Pirmani A; Ardeshirdavanai A; Forsberg L; Glaser A; McBurney R; Schmidt H; Bergmann AB; Braune S; Stahmann A; Middleton R; Salter A; Fox RJ; van der Walt A; Butzkueven H; Alroughani R; Ozakbas S; Rojas JI; van der Mei I; Nag N; Ivanov R; Sciascia do Olival G; Dias AE; Magyari M; Brum D; Mendes MF; Alonso RN; Nicholas RS; Bauer J; Chertcoff AS; Zabalza A; Arrambide G; Fidao A; Comi G; Peeters L Neurology; 2021 Nov; 97(19):e1870-e1885. PubMed ID: 34610987 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]